



Subscribe to follow us @ILPMP on YouTube

[View as Webpage](#)

## IDPH SIREN ALERT: MEDICATION-ASSISTED RECOVERY DOSING GUIDANCE



**Illinois ADVANCE** is composed of clinical pharmacists from the University of Illinois Chicago (UIC). They provide academic detailing services to prescribers and pharmacists via one-on-one in-person or virtual appointments. This team of pharmacists is trained to provide tailored, unbiased, up-to-date drug information and easy-to-use resources to assist clinicians in making evidence-based therapy decisions to optimize patient care. Appointments are 20 minutes in length and CME or CPE approved for 0.5 CEUs.

[CLICK TO READ SIREN ALERT](#)



In collaboration with IDPH and Illinois Advance, a SIREN was developed to address appropriate dosing for buprenorphine. Inadequate dosing or delays in treatment can lead to withdrawal symptoms, cravings, relapse, and increased risk of death. A 2023 review of the clinical research on the daily dose of sublingual buprenorphine demonstrated evidence that buprenorphine's dose-dependent benefits for treating opioid use disorder (OUD) can safely extend up to and potentially beyond 32mg/day. Inadequate dosing can result in relapses and return to illicit opioid use to treat uncontrolled cravings and withdrawal, increasing risk of unintended overdose and death.

Per SAMHSA, it is standard of care for all patients with OUD to be offered medication-assisted recovery (MAR), in particular buprenorphine and methadone, due to its effectiveness in reducing morbidity and mortality, irrespective of counseling engagement. The overdose crisis in Illinois impacts all communities, and there is a 20-fold increased risk of early death for patients with untreated OUD. All formulations of buprenorphine are evidence-based and lifesaving. The time immediately after discontinuation of buprenorphine treatment is associated with a markedly increased mortality risk. Therefore, inadequate dosing of buprenorphine or buprenorphine treatment interruptions are life-threatening and should be avoided to help mitigate the risk of death.

## PHARMACY DATA ENTRY PROCESS AFFECTS PRESCRIPTION MONITORING PROGRAM DATA, CLINICAL DECISION MAKING, AND DOWNSTREAM DATA ANALYSIS

The National Association of State Controlled Substances Authorities (NASCSA) supports, equips, and advocates for state-controlled substance authorities, prescription monitoring program administrators, and other members in their work to advance the public's health, safety, and welfare. Every state, along with certain districts and territories, operates a prescription monitoring program (PMP) - also known as a prescription drug monitoring program (PDMP) - that requires pharmacies to report prescription data. This course is intended to help pharmacists and pharmacy technicians understand the critical role they play in ensuring the

quality and integrity of PMP data that is used to improve patient safety across the nation.

Upon completion of this activity learners should be able to:

- Analyze the importance and value of complete, accurate data reported by dispensers to PMPs
- Evaluate how intentional or unintentional data entry errors and data omissions impact patient safety
- Discuss the downstream impacts of pharmacy-reported PMP data on clinical decision-making processes
- Identify and implement changes that can be made in their practice setting to improve PMP data integrity

Take advantage of this **FREE** ACPE accredited educational opportunity providing 1 hour of continuing education for **pharmacists** and **pharmacy technicians**.

[CLICK FOR MORE INFORMATION](#)

## ILPMP SELECTS UNIVERSITY PARTNER TO CONTINUE VIRTUAL ACADEMIC DETAILING VISITS FOR PEER REVIEW COMMITTEE

ILPMP has selected the University of Illinois Chicago (UIC) to conduct ongoing targeted virtual Academic Detailing visits for the ILPMP Peer Review Committee (PRC) through September 25, 2025. This 2-year opportunity for funding is through the Department of Justice 2023 Grant.

Targeted Academic Detailing education visits to identified prescribers will include topics on the background of opioid epidemic, CDC and other published opioid guidelines, overdose risk mitigation strategies, naloxone co-prescribing, opioid reversal standing order, and other related information deemed appropriate by the ILPMP.

The PRC is a subcommittee of the ILPMP Advisory Committee and is comprised of 10 members. Per Illinois statute, members may identify prescribers or dispensers who may be prescribing or dispensing outside the currently accepted medical standards of their professional practice and send the identified prescriber or dispenser a request for information regarding their prescribing or dispensing practices. This information is then used to determine if the prescriber would benefit from additional educational resources such as Academic Detailing.

## Educational Resources

### Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder

A three-hour program designed to meet the educational needs for physicians, nurses, and pharmacists. The program is accredited in 6, 30-minute modules.



# Continuing Education Program

## Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder

Session 1: Pain taxonomy, pathogenesis, and assessment  
Session 2: Developing a patient-centered pain treatment plan  
Session 3: Non-opioid analgesics: Evidence and clinical Pearls  
Session 4: Opioid analgesics: From A to Z  
Session 5: Clinical use of opioids: Safe prescribing and monitoring  
Session 6: The exit strategy: When the treatment becomes the problem

Faculty:  
June Oliver, MSN, APRN/CNS  
Laura Meyer-Junco, PharmD, BCPS, FASCP  
Chris Herndon, PharmD, BCACP, FCCP  
Camille Dunkley, MD, MHA, MS  
Noah Cooperstein, MD

[Prescriber Register](#)

[Pharmacist Register](#)



## Educational Support from UIC Clinical Pharmacists

Illinois ADVANCE is committed to developing collaborative relationships and providing current evidence-based drug information to improve prescribing and interdisciplinary patient care.



### Connect with Pharmacists

15 to 20 minute visits  
1:1 focused education  
Flexible scheduling



### Discuss New Evidence

Tools for prescribing decisions  
Relevant pharmacotherapy insights



### Get the latest information

Asthma SMART therapy  
Diabetes Mellitus  
Buprenorphine

Schedule a visit with Illinois ADVANCE today!




<https://illinoisadvance.com/>

# ILPMP.ORG & IL PMPnow Monthly Data

# WEBSITE DATA

APRIL 2024



## Contact Information

If you have questions about the information that appears in this update or suggestions for future content, please email [dhs.pmp@illinois.gov](mailto:dhs.pmp@illinois.gov). Visit [www.ilpmp.org](http://www.ilpmp.org) for more information.



*The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.*

Illinois Prescription Monitoring Program | 401 North Fourth Street | Springfield, IL 62702 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!